CHAPEL HILL, N.C., Nov. 3, 2011 /PRNewswire/ -- Pharmaceutical and biotechnology brand leaders are finding that some successful strategies for managing product lifecycle soon may no longer be viable, according to analysts at research and consulting firm Best Practices, LLC.
Early results from an ongoing Best Practices, LLC benchmarking study indicate that regulatory changes are undercutting the effectiveness of a number of proven strategies for extending pharmaceutical brand life, including fixed-dose combinations, new dosage regimens, contracting, extended release forms and publications.
With fewer products in the pipeline and more at the edge of the patent cliff, strategies that can extend the commercial life of mature brands are critical to bio-pharmaceutical companies today. When used correctly, lifecycle strategies can add as many as 10 years and billions of dollars to the life of an established or mature brand.
To identify which of 20+ strategies will continue to be feasible in the near future and which have the best return on investment, Best Practices, LLC, a world leader in biopharmaceutical benchmarking and best practice research, has opened its new benchmarking study to interested pharmaceutical and biotechnology executives and managers who have experience in brand lifecycle planning and management.
There is no cost to participate, and all benchmark participants will receive the complete, blinded research results and analysis for free. This study will generate comparative metrics and executive insights that participants can use in future brand lifecycle management planning and activities.
All responses are blinded and aggregated to protect confidentiality. To view or participate in the online survey, follow this link: http://www.surveygizmo.com/s/676582/maximizing-the-value-of-mature-bio-pharmaceutical-brands
For assistance or questions related to this study, contact research team leader Martha Haswell at [email protected] or (919) 767-9249. Responses are requested by November 14, 2011.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations. Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.
SOURCE Best Practices, LLC